
Antidote sounds like a franchise built to solve a problem. Avery228's first transactions offer a less dramatic picture: a roster built around Anthony Edwards, Jalen Brunson, and Franz Wagner, followed by a trade that turned a second-round pick into Onyeka Okongwu and Jaylon Tyson. There is no desperate overhaul here, no obvious obsession with collecting future selections, and no single position receiving all the attention. Antidote enters its first season with enough established players to compete immediately and enough younger talent to keep several different futures available.
That flexibility is impressive. It also leaves a question that will follow this franchise into October.
What exactly is Antidote trying to become?
The roster offers several answers, but the strongest one is fairly simple. Avery228 has assembled a team whose greatest advantage is the number of reasonable choices available every week. Its greatest weakness may be that those choices become much less important against opponents with a clearly superior starting nine.
Antidote can field a good lineup in several different ways. The next step is proving it can field a great one.
The First Five Tell Us Plenty
Avery228 used the first overall selection in June's dispersal draft on Anthony Edwards. Jalen Brunson followed as the second selection, then Franz Wagner, Ivica Zubac, and Pascal Siakam.
Those five selections established the foundation for the franchise.
Edwards provides the clearest long-term centerpiece. Brunson gives Antidote another established offensive option, while Wagner bridges the gap between proven production and future growth. Zubac and Siakam round out the group with frontcourt production and positional balance.
The order is revealing because Avery228 did not build exclusively around youth. There were younger players available throughout the dispersal pool, yet the first five selections produced a group designed to matter this season.
That distinguishes Antidote from another expansion franchise, Sam Presti's Burner. Matticus808 has reshaped its roster around a heavy Oklahoma City presence, younger players, and future draft ownership. Antidote's construction is more immediate. Edwards, Brunson, Wagner, Siakam, and Zubac already occupy five of its projected starting spots.
The roster suggests a competitive timetable rather than a prolonged rebuild.
Still, there is a distinction between choosing established players and assembling the league's strongest starting lineup.
HeHateMe can start Nikola Jokić, Stephen Curry, Cade Cunningham, and LeBron James. P. Giddey features Luka Dončić, Jaylen Brown, Bam Adebayo, Jalen Johnson, and Josh Giddey. Shane Gillis Alexander has Shai Gilgeous-Alexander alongside Alperen Sengun, Jalen Duren, Jamal Murray, and Lauri Markkanen.
Those opponents offer Antidote a difficult comparison. Edwards and Brunson provide a strong opening argument, but Avery228 still needs the surrounding lineup to deliver enough production to close the gap.
Antidote belongs in the conversation about competitive rosters. Its top-end strength has not yet earned a place among the league's most imposing groups.
What does this franchise believe it is building?
The Trade That Explains the Roster
The clearest example of Antidote's early construction came in June, when Avery228 sent its 2026 second-round pick to brodiedean8 for Onyeka Okongwu and Jaylon Tyson.
The deal matters because it shows the type of roster improvement Antidote prioritized.
Okongwu joins a center group already featuring Zubac and Deandre Ayton. Tyson adds another option around a group that includes Wagner, OG Anunoby, RJ Barrett, and Josh Hart.
Rather than concentrating value in one additional top-tier player, Antidote used a draft selection to secure two rostered players who could provide alternatives when setting its lineup.
For a new franchise, that is a defensible approach. A team still learning how its players fit together benefits from having several options at the same position. Depth reduces the damage when a player's production disappoints or availability changes.
But the transaction also reveals the limitation of this construction.
Okongwu and Tyson improve the roster's range of possibilities. Neither arrives with a guaranteed place above the established players already in Antidote's projected lineup. Their value depends partly on whether Avery228 can turn that additional depth into useful weekly production.
The best counterargument is that this is precisely what a fantasy roster should look like. Depth matters across a long regular season, and a team with quality alternatives can adjust without needing to make a trade every time circumstances change.
That's fair. Antidote's bench might be among its strongest competitive advantages.
The problem appears when depth stops providing a clear improvement to the starting lineup. Against Jokić or Dončić, having another reasonable option at center or guard does not automatically close the difference in top-end fantasy production.
Avery228 can choose between multiple useful players. Its opponents may have fewer difficult decisions because their best options are more obvious.
That distinction could decide whether Antidote becomes a playoff threat or a team that consistently looks stronger on its roster page than it does in individual matchups.
Nine Starters, Too Many Alternatives
Consider the projected starting group.
Jalen Brunson and Dejounte Murray occupy the point guard positions. Anthony Edwards, Derrick White, and Josh Hart fill the shooting guard slots. Franz Wagner starts at small forward, Pascal Siakam at power forward, and Ivica Zubac alongside Cameron Boozer at center.
Then examine the bench.
Payton Pritchard, Andrew Nembhard, Jordan Poole, Cam Thomas, and Scotty Pippen provide additional guard options. RJ Barrett and OG Anunoby offer wing and forward depth. Okongwu and Ayton give Antidote multiple alternatives at center.
For a franchise entering its first season, that is an unusually extensive collection of lineup options.
It also means some players with legitimate fantasy utility will remain outside the projected starting nine.
That creates a different challenge from the one facing Coopa Troopas, which has Cooper Flagg, Brandon Miller, Donovan Clingan, AJ Dybantsa, and Darius Acuff spread across its present and future plans. Coopa Troopas must determine how its younger players develop into reliable weekly contributors. Antidote already possesses a larger group of established alternatives and must decide which ones actually deserve priority.
Cameron Boozer makes the situation especially interesting.
Avery228 selected Boozer first overall in the league's 2026 rookie draft. He now occupies a projected starting center position alongside Zubac, with Okongwu and Ayton available behind them.
Antidote has room to use Boozer immediately, but it does not need to depend exclusively on him for center production. That is an attractive arrangement for a dynasty franchise introducing a rookie into its competitive lineup.
The uncertainty is what happens if the alternatives prove more useful in the short term.
Avery228 could prioritize immediate production and use a more established center. It could continue starting Boozer while accepting the uncertainty that comes with a young player. Neither approach is inherently wrong, but the choice would tell us considerably more about Antidote than the team name does.
The first lineup decisions will reveal whether the franchise intends to maximize every available matchup or give certain younger players a larger role in its long-term plans.
There is no evidence yet of which approach Avery228 will take.
The Future Is Stronger in Players Than Picks
Antidote's long-term position deserves a closer examination because its roster can easily create the impression of a team loaded with every kind of future asset.
That is not quite what the ledger shows.
Avery228 currently holds brodiedean8's 2027 second-round pick and alecb5's 2027 third-round pick among its explicitly listed acquired selections. Its own 2026 second-round pick has already been used, and its future pick ownership does not establish a collection of additional first-round selections.
Other franchises have greater documented flexibility through future first-round picks.
Coopa Troopas holds 2027 and 2028 first-round selections originally belonging to 44Colt, along with brodiedean8's 2028 first. Sam Presti's Burner holds first-round picks from goochshot in 2027, alecb5 in 2028, and 44Colt in 2029.
Antidote's future is concentrated much more heavily in the players currently occupying roster spots.
That includes Edwards, Wagner, Boozer, and the developmental possibilities represented by Cam Whitmore and Shaedon Sharpe. Their long-term value gives Antidote ways to improve without necessarily depending on another major draft.
There is a trade-off.
If Antidote becomes a contender immediately, that concentration is convenient. Its established players can contribute now while its younger pieces potentially grow into larger roles.
If the team falls short of the strongest contenders, however, Avery228 may have fewer documented premium draft assets available to reshape the roster without trading players.
That makes its depth important in a second way. Antidote has several players who could become trade candidates if the franchise eventually decides that improving its strongest starting spots matters more than preserving numerous alternatives.
The June Okongwu and Tyson deal expanded the number of useful roster options. A future deal might have to work in the opposite direction, turning multiple players into one clearly stronger starter.
Nothing in the current transactions establishes that Avery228 intends to make such a move.
But the structure of the roster makes that decision worth watching.
The Difference Between Being Ready and Being Finished
There is a reasonable case that Antidote should avoid major changes altogether.
The franchise has never played a fantasy regular-season matchup under its new GM. Its projected lineup has not produced a single result. Avery228 cannot yet know which combinations will work best in this league's format or whether its apparent surplus at certain positions will survive the demands of a full season.
Brunson, Edwards, and Wagner give the roster a strong base. Siakam, White, Hart, and Zubac offer additional starting options. Boozer introduces another potential long-term contributor.
The bench provides alternatives without forcing Antidote to sacrifice the core.
That is a good position for a new franchise.
The strongest reason to be skeptical is the competition. HeHateMe, P. Giddey, Shane Gillis Alexander, and Shep and Co. can all assemble formidable projected starting groups. The Injury Report also has Giannis Antetokounmpo, Devin Booker, Karl-Anthony Towns, Evan Mobley, and Kawhi Leonard.
Antidote cannot expect a place above those teams simply because it has more playable options.
Its strongest path to exceeding expectations probably runs through the performance of its supporting starters. If White, Hart, Zubac, and Siakam consistently contribute enough to complement Edwards, Brunson, and Wagner, Avery228 can compete without needing one superstar to carry every matchup.
If those supporting pieces fall short, the team will face a more difficult choice: preserve the flexibility of the current roster or pursue greater star concentration through trades.
The decision becomes even more important because Antidote does not have the same documented reserve of future first-round picks that some rivals possess.
Its construction gives Avery228 several ways to respond to a disappointing start. It does not guarantee that any of those responses will produce the elite player required to change the team's ceiling.
What We Don't Know Yet
Avery228 enters the 2026 season without an established league identity.
There is no previous record to interpret, no playoff exit to explain, and no history of lineup decisions from which to build a theory about the GM's preferences.
The dispersal selections and the Okongwu-Tyson trade are the available evidence. They describe a roster with considerable depth, a strong established core, a meaningful group of younger players, and fewer documented future first-round assets than several competitors.
They do not tell us how Avery228 will react to losing matchups, which players will become untouchable, or whether the franchise will eventually sacrifice depth to pursue a higher ceiling.
Those questions matter because the roster appears capable of competing before its competitive hierarchy is fully settled.
Avery228 has time to learn which players deserve its starting spots. It also has a league filled with opponents whose strongest players can make those decisions painfully clear.
Antidote begins with options. Its first real identity will emerge from the ones Avery228 stops keeping open.
Reported from 4 approved sources in the league record.
Lauren Blake
Franchise Identity Writer
Team culture, rebrands, self-concept, organizational voice
What this is built on
Every claim here is grounded in real league data. The receipts:
- SleeperCurrent standings
- LoreFranchise lore
- ArticleRecent related coverage
- SleeperLeague database (Sleeper sync)
See something wrong?
Every claim here is grounded in real data. If we got one wrong, tell us.
